Literature DB >> 22861670

Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.

Andrew Tomlin1, David Reith, Susan Dovey, Murray Tilyard.   

Abstract

BACKGROUND: Examination of clinical data routinely recorded in general practice provides significant opportunities for identifying and quantifying medicine-related adverse events not captured by spontaneous adverse reaction reporting systems. Robust pharmacovigilance methods for detecting and monitoring adverse events due to treatment with new and existing medicines are required to estimate the true extent of adverse events experienced by primary care patients.
OBJECTIVES: The aim of the study was to examine evidence of adverse events contained in general practice electronic records and to study observed events related to selective serotonin reuptake inhibitors (SSRIs) as an example of drug-specific pharmaceutical surveillance achievable with these data.
METHODS: Electronic clinical records for a cohort of 338 931 patients consulting from 2002 to 2007 were extracted from the patient management systems of 30 primary care clinics in New Zealand. Medical warnings files, prescription records and free text consultation notes were used to identify physician-recorded treatment cautions, including adverse events and medicines they were associated with. A structured chronological analysis of prescriptions, consultation notes and adverse events relating to patients prescribed the SSRI citalopram was undertaken, and included investigating reasons for switching treatment to another SSRI (fluoxetine or paroxetine) as a method for detecting evidence of drug safety signals. We compared the number of adverse events identified for patients at one practice with the number spontaneously reported to New Zealand's Centre for Adverse Reactions Monitoring (CARM).
RESULTS: During the 6-year study period, 173 478 patients received 4 811 561 prescriptions. There were 37 397 allergies, adverse events and other warnings recorded for 24 994 patients (7.4%); adverse events relating to 65 different types of drug were reported. Medicines most frequently implicated in adverse event reports were antibacterials, analgesics, antihypertensive medicines, lipid-modifying agents and skin preparations. Citalopram was prescribed for 5612 patients, and 701 adverse events relating to citalopram were identified in the electronic health records of 473 (8.4%) patients. A total of 713 (12.7%) patients changed treatment from citalopram to another SSRI, and 164 reasons for the switch were identified: suspected adverse drug effects for 129 (78.7%), lack of effect for 29 (17.7%) and patient preference for 6 (3.7%). The most common adverse events preceding the switch were anxiety, nausea and headaches. Of the 725 adverse events and medical warnings recorded at one practice, 21 (2.9%) were spontaneously reported to the CARM.
CONCLUSIONS: Routinely recorded general practice data provide a wealth of opportunities for monitoring drug safety signals and for other patient safety issues. Medical warning records and consultation notes contain a wealth of information on adverse events but structured search methodologies are often required to identify these.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22861670     DOI: 10.1007/bf03261970

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  29 in total

1.  Innovations for the future of pharmacovigilance.

Authors:  June S Almenoff
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 2.  The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database.

Authors:  A Bate; M Lindquist; I R Edwards
Journal:  Fundam Clin Pharmacol       Date:  2008-02-01       Impact factor: 2.748

Review 3.  Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.

Authors:  Desiree L Kunac; Mira Harrison-Woolrych; Michael V Tatley
Journal:  N Z Med J       Date:  2008-10-03

4.  Developing the Sentinel System--a national resource for evidence development.

Authors:  Rachel E Behrman; Joshua S Benner; Jeffrey S Brown; Mark McClellan; Janet Woodcock; Richard Platt
Journal:  N Engl J Med       Date:  2011-01-12       Impact factor: 91.245

5.  Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases.

Authors:  Stephanie J Reisinger; Patrick B Ryan; Donald J O'Hara; Gregory E Powell; Jeffery L Painter; Edward N Pattishall; Jonathan A Morris
Journal:  J Am Med Inform Assoc       Date:  2010 Nov-Dec       Impact factor: 4.497

6.  Trends in the use of inhaled corticosteroids for childhood asthma in New Zealand.

Authors:  Maria Johansson; Jason Hall; David Reith; Pam Jackson; Murray Tilyard
Journal:  Eur J Clin Pharmacol       Date:  2003-08-23       Impact factor: 2.953

Review 7.  Pharmacovigilance: methods, recent developments and future perspectives.

Authors:  L Härmark; A C van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2008-06-04       Impact factor: 2.953

8.  Computerized surveillance of adverse drug events in hospital patients.

Authors:  D C Classen; S L Pestotnik; R S Evans; J P Burke
Journal:  JAMA       Date:  1991-11-27       Impact factor: 56.272

9.  Comparison of potency of inhaled beclomethasone and budesonide in New Zealand: retrospective study of computerised general practice records.

Authors:  B D Pethica; A Penrose; D MacKenzie; J Hall; R Beasley; M Tilyard
Journal:  BMJ       Date:  1998-10-10

Review 10.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

View more
  3 in total

1.  Using Electronic Health Records to Identify Adverse Drug Events in Ambulatory Care: A Systematic Review.

Authors:  Chenchen Feng; David Le; Allison B McCoy
Journal:  Appl Clin Inform       Date:  2019-02-20       Impact factor: 2.342

2.  Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring.

Authors:  Sue Jordan; Marie Gabe; Louise Newson; Sherrill Snelgrove; Gerwyn Panes; Aldo Picek; Ian T Russell; Michael Dennis
Journal:  ScientificWorldJournal       Date:  2014-02-23

Review 3.  Adverse drug reactions in primary care: a scoping review.

Authors:  H Khalil; C Huang
Journal:  BMC Health Serv Res       Date:  2020-01-06       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.